MINI-FOCUS: INFLAMMATION IN CARDIAC INJURY The IL-1b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

Abstract : HIGHLIGHTS Immediate IL-1b antibody gevokizumab administration reduces ischemia/ reperfusion related infarct size. Immediate and late IL-1b antibody gevokizumab administration improves heart failure related left ventricular remodeling. IL-1b antibody gevokizumab improves heart failure related coronary dysfunction. From
Complete list of metadatas

Cited literature [51 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02296604
Contributor : Ebba Brakenhielm <>
Submitted on : Wednesday, September 25, 2019 - 12:34:25 PM
Last modification on : Thursday, September 26, 2019 - 1:19:40 AM

File

Gevokizumab.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Najah Harouki, Lionel Nicol, Isabelle Remy-Jouet, Jean-Paul Henry, Anaïs Dumesnil, et al.. MINI-FOCUS: INFLAMMATION IN CARDIAC INJURY The IL-1b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. J Am Coll Cardiol Basic Trans Science, 2017, 2 (4), pp.418 - 448. ⟨10.1016/j.jacbts.2017.06.005⟩. ⟨inserm-02296604⟩

Share

Metrics

Record views

12

Files downloads

20